Brief: Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH
16/06/2025 12:39
June 16 (Reuters) - Gossamer Bio Inc GOSS.O: GOSSAMER BIO ANNOUNCES COMPLETION OF ENROLLMENT IN REGISTRATIONAL PHASE 3 PROSERA STUDY FOR THE TREATMENT OF PAH GOSSAMER BIO INC - TOPLINE RESULTS FROM PHASE 3 PROSERA STUDY EXPECTED FEBRUARY 2026 Source text: ID:nBw7P10V0a Further company coverage: GOSS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing